Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Systemic Treatment
100%
Clinical Characterization
100%
Recurrence Rate
100%
HLA B27-associated Uveitis
100%
Colombia
50%
Uveitis
50%
Clinical Characteristics
33%
Methotrexate
33%
Disease-modifying Antirheumatic Drugs (DMARDs)
33%
Clinical Spectrum
33%
Recurrent Cases
33%
Colombian Patients
16%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
16%
Demographic Characteristics
16%
Therapeutic Strategies
16%
Descriptive Statistics
16%
Etiology
16%
Referral Center
16%
Therapeutic Potential
16%
Systemic Symptoms
16%
Systemic Disease
16%
Fisher's Exact Test
16%
Anterior Chamber
16%
Adalimumab
16%
Latin American Populations
16%
Treatment Strategy
16%
Cataract
16%
Biological Agents
16%
Macular Edema
16%
Old Age
16%
Female Predominance
16%
Chi-square Test
16%
Spearman Correlation
16%
Common Complications
16%
Follow-up Time
16%
Mydriatics
16%
Age at Presentation
16%
Hypopyon
16%
Posterior Synechiae
16%
Topical Corticosteroids
16%
Fibrinous Reaction
16%
Medicine and Dentistry
Uveitis
100%
Cross Sectional Study
100%
HLA-B27
100%
Systemic Therapy
100%
Recurrence Risk
100%
Recurrent Disease
22%
Methotrexate
22%
Disease Modifying Antirheumatic Drug
22%
Diseases
11%
Vitreous
11%
Patient Referral
11%
Topical Corticosteroid
11%
Systemic Disease
11%
Fisher Exact Test
11%
Anterior Chamber of Eyeball
11%
Adalimumab
11%
Cataract
11%
Macular Edema
11%
Nonsteroid Antiinflammatory Agent
11%
Chi Square Test
11%
Mydriatic Agent
11%
Etiology
11%
Hypopyon
11%
Eye Synechia
11%
Pharmacology, Toxicology and Pharmaceutical Science
Uveitis
100%
Systemic Treatment
100%
Recurrence Risk
100%
Cross-Sectional Study
100%
Recurrent Disease
22%
Disease Modifying Antirheumatic Drug
22%
Methotrexate
22%
Diseases
11%
Non-Steroidal Anti-Inflammatory Drug
11%
Systemic Disease
11%
Cataract
11%
Macular Edema
11%
Adalimumab
11%
Topical Corticosteroid
11%
Etiology
11%
Mydriatic Agent
11%
Eye Synechia
11%
Hypopyon
11%
Immunology and Microbiology
Uveitis
100%
HLA-B27
100%
Methotrexate
22%
Disease-Modifying Antirheumatic Drug
22%
Adalimumab
11%